Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8810834 | 0.81 | CYP1A2 (0.53) | TOP1MEN1KMT2AMAPK1 | |
| SCHEMBL3736280 | 0.79 | TOP1 (0.48) | TOP1DRD2GAAHTR2AMAPK1 | |
| SCHEMBL3738458 | 0.78 | TOP1 (0.64) | TOP1 | |
| SCHEMBL3746336 | 0.77 | TOP1 (0.46) | TOP1MEN1KMT2AMAPTGAA | |
| SCHEMBL3748969 | 0.75 | TOP1 (0.51) | TOP1MAPTGAAMAPK1 | |
| SCHEMBL16895266 | 0.73 | ABCG2 (0.53) | TOP1MEN1KMT2AMAPTMAPK1 | |
| SCHEMBL16895275 | 0.71 | KMT2A (0.50) | MEN1KMT2AMAPTADORA2AL3MBTL1 | |
| SCHEMBL3733796 | 0.70 | GUSB (0.52) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL16895262 | 0.70 | MAPT (0.63) | MEN1KMT2AMAPTGAAMAPK1 | |
| SCHEMBL16895271 | 0.69 | ALDH1A1 (0.56) | MAPTGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | RECQL 17/4885TOP1 265/4885KDR 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.